Can next-generation antibodies offset biosimilar competition?

被引：0
|
作者：
Asher Mullard
机构：
来源：
Nature Reviews Drug Discovery | 2012年 / 11卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
With the first biosimilar version of a monoclonal antibody now under regulatory review in the European Union, which R&D strategies are innovators relying on to counteract competition?
引用
收藏
页码：426 / 428
页数：2
相关论文
共 50 条
  • [1] Can next-generation antibodies offset biosimilar competition?
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (06) : 426 - 428
  • [2] Next-generation antibodies
    Evans, James B.
    Syed, Basharut A.
    NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (06) : 413 - 414
  • [3] Next-generation antibodies
    James B. Evans
    Basharut A. Syed
    Nature Reviews Drug Discovery, 2014, 13 : 413 - 414
  • [4] Biosimilar, biobetter and next generation therapeutic antibodies
    Beck, Alain
    MABS, 2011, 3 (02) : 107 - 110
  • [5] Rabbit monoclonals: Next-generation antibodies
    Zhang, DX
    Selwood, SP
    Pytela, R
    GENETIC ENGINEERING NEWS, 2004, 24 (06): : 36 - 36
  • [6] Polybodies: Next-generation clinical antibodies
    Pande, Abhay H.
    Sandeep
    Shinde, Suraj H.
    DRUG DISCOVERY TODAY, 2024, 29 (12)
  • [7] MONOCLONAL-ANTIBODIES PROGRESS TO THE NEXT-GENERATION
    MCNEIL, C
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (23) : 1738 - 1739
  • [8] Glycoengineered antibodies: towards the next-generation of immunotherapeutics
    Mastrangeli, Renato
    Palinsky, Wolf
    Bierau, Horst
    GLYCOBIOLOGY, 2019, 29 (03) : 199 - 210
  • [9] Witnessing Major Growth in Next-Generation Antibodies
    Challener, Cynthia A.
    BIOPHARM INTERNATIONAL, 2017, 30 (04) : 14 - 19
  • [10] Engineered mRNA and the Rise of Next-Generation Antibodies
    Sanz, Laura
    Alvarez-Vallina, Luis
    ANTIBODIES, 2021, 10 (04)
12345